GENOMES & DISEASE
'We investigate the patterns and mechanisms of genomic variation in disease'
Juan Ruiz-Bañobre is a physician (medical oncologist)-scientist in the Medical Oncology Department of the University Clinical Hospital of Santiago de Compostela - Oncomet group. As a principal investigator in the Genomes and Disease group, his role is to bridge the gap between practicing clinicians and biomedical scientists to bring discoveries from bench to bedside (and back again) in the field of oncology.
His main research interests include the development of molecular predictive biomarkers for various antineoplastic agents, the understanding of cancer evolution from multi-omics and immunological perspectives, as well as the development and translation of novel liquid biopsies approaches to help in cancer patient management. From a clinical and translational viewpoint, he is primarily focused on gastrointestinal cancers, genitourinary malignancies, and hereditary cancer predisposition syndromes.
Selected publications (last 5 years):
Ruiz-Bañobre J, Goel A. 2021. Genomic and epigenomic biomarkers in colorectal cancer: From diagnosis to therapy. Advances in CancerResearch. Academic Press, Elsevier. ISBN 0065-230. https://doi.org/10.1016/bs.acr.2021.02.008
Ruiz-Bañobre J #, Molina-Díaz A, Fernández-Calvo O, et al. Rethinkingprognostic factors in locally advanced or metastatic urothelial carcinomain the immune checkpoint blockade era: a multicenter retrospectivestudy.ESMO Open.2021;6(2):100090. doi: https://doi.org/10.1016/j.esmoop.2021.100090 # Corresponding author.
Ruiz-Bañobre J, Roy R, Alustiza Fernández M, et al. Clinical significance of a microRNA signature for the identification and predicting prognosis in colorectal cancers with mucinous differentiation. Carcinogenesis.2020;41(11):1498-1506. doi:10.1093/carcin/bgaa097]
Arias Ron D, Areses Manrique MC, Mosquera Martínez J, García González J, Afonso Afonso FJ, Lázaro Quintela M, Fernández Núñez N, Azpitarte Raposeiras C, Amenedo Gancedo M, Santomé Couto L, García Campelo MR, Muñoz Iglesias J, Ruiz-Bañobre J, et al. Efficacy and safety of Nivolumab in older patients with pretreated lung cancer: A subgroupanalysis of the Galician lung cancer group. J Geriatr Oncol. 2020. doi:https://doi.org/10.1016/j.jgo.2020.11.010
García-González J * #, Ruiz-Bañobre J * #, Afonso-Afonso FJ, et al. PD-(L)1 Inhibitors in Combination with Chemotherapy as First-Line Treatment for Non-Small-Cell Lung Cancer: A Pairwise Meta-Analysis. J Clin Med.2020;9(7). doi:10.3390/jcm9072093 * Co-first author. # Co-corresponding author.
Ruiz-Bañobre J, Goel A. DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers. Gastroenterology. February 2019. doi:10.1053/j.gastro.2018.11.071
Ruiz-Bañobre J, Kandimalla R, Goel A. Predictive Biomarkers in Metastatic Colorectal Cancer: A Systematic Review. JCO Precis Oncol. 2019;(3):1-17. doi:10.1200/PO.18.00260
Ruiz-Bañobre J #, Areses-Manrique MC, Mosquera-Martínez J, et al. Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy. Transl Lung Cancer Res Vol 8, No 6 (December 2019) Transl Lung Cancer Res. 2019 #Corresponding author.
Reimondez-Troitiño S, González-Aramundiz JV, Ruiz-Bañobre J, et al. Versatile protamine nanocapsules to restore miR-145 levels and interfere tumor growth in colorectal cancer cells. Eur J Pharm Biopharm. 2019;142:449-459. doi:https://doi.org/10.1016/j.ejpb.2019.07.016
Vázquez-Ríos AJ, Alonso-Nocelo M, López-Bouzo B, Ruiz-Bañobre J, de la Fuente-Freire M. 2018. Chapter 8: Nanotheranostics and Their Potential in the Management of Metastatic Cancer Handbook of Nanomaterials for Cancer Theranostics. Elsevier. ISBN 9780128133392
López-López R, Ruiz-Bañobre J, Muinelo-Romay L. 2018. Capítulo 3: Biopsia tisular versus biopsia líquida 50 Preguntas Clave en Oncología de Precisión. Permanyer. ISBN 9788417221416
Vidal J, Muinelo L, Dalmases A, Jones F, Edelstein D, Iglesias M, Orrillo M, Abalo A, Rodríguez C, Brozos E, Vidal Y, Candamio S, Vázquez F, Ruiz-Bañobre J, et al. Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Ann Oncol. 2017;28(6):1325-1332
Ruiz-Bañobre J #, Garcia-Gonzalez J. Anti-PD-1/PD-L1-induced psoriasis from an oncological perspective. J Eur Acad Dermatol Venereol. 2017;31(9):e407-e408. doi:10.1111/jdv.14217 #Corresponding author.
Ruiz-Bañobre J #, Abdulkader I, Anido U, Leon L, Lopez-Lopez R, Garcia-Gonzalez J. Development of de novo psoriasis during nivolumab therapy for metastatic renal cell carcinoma: immunohistochemical analyses and clinical outcome. APMIS. 2017;125(3):259-263. doi:10.1111/apm.12658 #Corresponding author.
Ruiz-Bañobre J #, Pérez-Pampín E, García-González J, et al. Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature. Lung Cancer. 2017;0(0). doi:10.1016/j.lungcan.2017.04.007 #Corresponding author.
Ruiz-Bañobre J #, Anido U, García-González J. Re: Francesco Piva, Matteo Santoni, Marina Scarpelli, et al’s Letter to the Editor re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcom. Eur Urol. July 2016. doi:10.1016/j.eururo.2016.06.038 13 #Corresponding author.
